# Phagocyte Defects and Chronic Granulomatous Disease
## Overview of Phagocyte Function
Phagocytes, encompassing neutrophils, monocytes, and macrophages, constitute a critical arm of the innate immune defense against bacterial and fungal pathogens. The phagocyte response follows a highly coordinated sequence of events that begins with the production and release of these cells from the bone marrow, continues through chemotaxis and directed migration toward sites of infection, proceeds through adhesion to vascular endothelium and transmigration into tissues, and culminates in the engulfment of pathogens by phagocytosis followed by intracellular killing through both oxidative and non-oxidative mechanisms. Each of these steps is governed by distinct molecular machinery, and defects at any point along this cascade produce characteristic clinical syndromes with unique infectious susceptibilities and diagnostic signatures.
The overarching clinical pattern shared across phagocyte disorders includes susceptibility to deep-seated bacterial and fungal infections, poor pus formation in certain conditions where neutrophils cannot reach or function at sites of infection, and delayed wound healing. Recognizing these patterns is essential for the clinical immunologist, as early diagnosis and targeted management can profoundly alter outcomes in what are otherwise life-threatening conditions.
## Chronic Granulomatous Disease (CGD)
### Genetics and Pathophysiology
Chronic granulomatous disease arises from defects in the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex, the multi-component enzyme responsible for generating the superoxide anion (O2-) that initiates the respiratory burst within the phagosome. The NADPH oxidase consists of membrane-bound and cytoplasmic components that must assemble on the phagosomal membrane upon phagocyte activation. The gp91phox subunit, encoded by CYBB on the X chromosome, forms the catalytic core of the oxidase together with the p22phox subunit (encoded by CYBA), and together these constitute cytochrome b558. Upon cellular activation, the cytoplasmic subunits p47phox (NCF1), p67phox (NCF2), p40phox (NCF4), and the small GTPase Rac2 translocate to the membrane and associate with the cytochrome to form the functional holoenzyme.
The most common form of CGD is X-linked, caused by mutations in CYBB encoding gp91phox, and accounts for approximately 65% of all cases. This form tends to present with the most severe clinical phenotype. Autosomal recessive forms include defects in p47phox (NCF1), which accounts for approximately 25% of cases and often manifests with a somewhat milder clinical course, as well as less common mutations in p22phox (CYBA), p67phox (NCF2), and the rare p40phox (NCF4) deficiency.
The central pathophysiologic consequence of NADPH oxidase dysfunction is that phagocytes can successfully ingest microorganisms but cannot generate the reactive oxygen species necessary for intracellular killing. This impairment is particularly consequential for catalase-positive organisms. These pathogens produce catalase, an enzyme that degrades hydrogen peroxide. In normal circumstances, even when the phagocyte oxidase is impaired, some hydrogen peroxide generated by the bacteria themselves can contribute to microbicidal activity within the phagosome. However, catalase-positive organisms such as Staphylococcus aureus, Aspergillus species, Serratia marcescens, Burkholderia cepacia, and Nocardia consume their own hydrogen peroxide, thereby depriving the phagocyte of this compensatory killing mechanism. A useful mnemonic for the classic CGD pathogens is "SSAN" -- Staphylococcus, Serratia, Aspergillus, and Nocardia. In contrast, catalase-negative organisms such as streptococci generate hydrogen peroxide that accumulates within the phagosome and can partially compensate for the absent oxidase, rendering CGD patients relatively less susceptible to these pathogens.
### Clinical Features
The age of presentation and disease severity correlate with the specific genetic defect and the degree of residual NADPH oxidase activity. X-linked CGD due to gp91phox mutations typically presents within the first two years of life, whereas autosomal recessive forms, particularly p47phox deficiency, may present later in childhood or even in early adulthood.
The infectious complications of CGD are characteristic and recurrent. Pneumonia is the most common serious infection, with Aspergillus fumigatus representing the leading cause of mortality in CGD. Staphylococcal pneumonia is also frequent. Liver abscesses, typically caused by S. aureus, are a hallmark of CGD and may demonstrate a characteristic "target sign" on computed tomography, with a peripheral rim of enhancement surrounding the central abscess cavity. Suppurative lymphadenitis, frequently caused by S. aureus or Serratia, is another common presentation. Osteomyelitis in CGD has a predilection for the small bones of the hands and feet and is often caused by Serratia or Aspergillus, in contrast to the typical long-bone involvement seen in otherwise healthy children with hematogenous osteomyelitis. Cutaneous manifestations include recurrent skin abscesses, perirectal abscesses, and impaired wound healing. Septicemia may occur with Burkholderia cepacia, Salmonella, or Staphylococcus.
Beyond infectious complications, CGD is notable for the formation of granulomas, which arise from the excessive and persistent inflammatory response to antigens that the phagocytes cannot effectively clear. These granulomas can cause clinically significant obstruction, particularly in the gastrointestinal and genitourinary tracts. CGD colitis mimics Crohn's disease both clinically and histologically, featuring non-caseating granulomas and transmural inflammation, and may cause significant morbidity with strictures and obstruction. Genitourinary granulomas can produce ureteral or bladder outlet obstruction. Autoimmune manifestations, including a discoid lupus-like rash, are observed particularly in female carriers of X-linked CGD, who demonstrate a mosaic pattern of normal and deficient neutrophils due to X-chromosome inactivation. In countries where routine Bacillus Calmette-Guerin (BCG) vaccination is practiced, disseminated BCG infection may be the initial presentation of CGD.
### Diagnosis
The dihydrorhodamine (DHR) flow cytometry assay is the current gold standard screening test for CGD. In this assay, the non-fluorescent compound dihydrorhodamine 123 is loaded into neutrophils, which are then stimulated with phorbol myristate acetate (PMA) to activate the NADPH oxidase. In normal neutrophils, the reactive oxygen species generated by the oxidase convert DHR to the fluorescent compound rhodamine 123, producing a measurable shift in fluorescence intensity. In CGD, stimulated neutrophils show absent or markedly reduced fluorescence, reflecting the failure of superoxide generation. The DHR assay offers several advantages over older methods: it can detect X-linked carrier mothers, who demonstrate a characteristic bimodal fluorescence pattern reflecting the coexistence of normal and oxidase-deficient neutrophil populations due to random X-chromosome inactivation. It can also distinguish between X-linked CGD, which shows complete absence of fluorescence, and autosomal recessive p47phox deficiency, which often demonstrates a small amount of residual low-level fluorescence.
The nitroblue tetrazolium (NBT) test was the historical screening method for CGD. In this assay, yellow-colored NBT is reduced to blue-purple formazan by the superoxide generated during the respiratory burst. While the NBT test remains in use in some resource-limited settings, it is less sensitive and less quantitative than DHR flow cytometry and has been largely supplanted. Genetic testing should be performed to confirm the specific NADPH oxidase subunit affected, as this has important implications for prognosis, inheritance counseling, and eligibility for curative therapies.
| CGD Subtype | Gene | Protein | Inheritance | Frequency | Clinical Severity |
|---|---|---|---|---|---|
| X-linked (most common) | CYBB | gp91phox | X-linked | ~65% | Most severe |
| AR p47phox deficiency | NCF1 | p47phox | AR | ~25% | Milder; residual oxidase activity |
| AR p22phox deficiency | CYBA | p22phox | AR | Rare | Severe |
| AR p67phox deficiency | NCF2 | p67phox | AR | Rare | Variable |
| AR p40phox deficiency | NCF4 | p40phox | AR | Very rare | Mild |
### Treatment
The management of CGD involves lifelong antimicrobial prophylaxis, immunomodulatory therapy, aggressive treatment of acute infections, management of inflammatory complications, and consideration of definitive curative approaches. Antimicrobial prophylaxis forms the foundation of CGD management and should be administered from the time of diagnosis throughout the patient's life. Trimethoprim-sulfamethoxazole provides anti-staphylococcal and anti-Nocardia prophylaxis and has been shown to reduce the incidence of serious bacterial infections by approximately 50%. Itraconazole provides anti-Aspergillus prophylaxis and reduces the incidence of invasive fungal infections by approximately 70%.
Interferon-gamma (IFN-gamma, marketed as Actimmune) is administered at a dose of 50 micrograms per square meter of body surface area subcutaneously three times per week. The landmark International CGD Study Group trial, published in the New England Journal of Medicine in 1991, demonstrated that IFN-gamma therapy reduced the incidence of serious infections by approximately 70%. The mechanism of IFN-gamma's benefit in CGD remains debated; it may not directly augment superoxide production but rather enhances non-oxidative killing mechanisms within phagocytes. Common side effects include fever, myalgia, and headache, constituting a flu-like syndrome that is generally manageable with antipyretics and typically diminishes with continued therapy.
Treatment of acute infections requires aggressive antimicrobial therapy with prolonged courses. Invasive aspergillosis may require weeks to months of antifungal therapy, with voriconazole serving as the first-line agent for this indication. Granulocyte transfusions from healthy donors may be considered for life-threatening infections that are unresponsive to antimicrobial therapy alone. Corticosteroids are employed for the management of obstructive granulomas affecting the gastrointestinal or genitourinary tract, though they should be used in short courses and with careful attention to the inherent infection risk in these patients.
Hematopoietic stem cell transplantation (HSCT) is curative for CGD and is increasingly recommended, particularly for patients with the severe X-linked form. Reduced-intensity conditioning protocols have significantly improved transplant outcomes, and recent series using matched sibling donors report survival rates exceeding 90%. Gene therapy for X-linked CGD is under active investigation in clinical trials using lentiviral vectors targeting the gp91phox gene, and early results have been promising.
A diagram of the NADPH oxidase complex in neutrophils showing normal function versus CGD. Left panel (normal): neutrophil engulfing a bacterium into a phagosome. NADPH oxidase complex assembled on phagosomal membrane: gp91phox and p22phox spanning the membrane (cytochrome b558), with p47phox, p67phox, p40phox, and Rac2 recruited from cytoplasm upon activation. Electron transfer from NADPH to O2 generating superoxide (O2-), which is converted to H2O2 by SOD, then to HOCl by myeloperoxidase. Bacterial killing shown. Right panel (CGD): same setup but with a red X on gp91phox (X-linked CGD most common), showing absent superoxide production. Bacterium (labeled catalase-positive: S. aureus) survives inside phagosome. Inset: DHR flow cytometry comparison showing normal (bright fluorescence shift) vs CGD (no shift). List of catalase-positive organisms: Staphylococcus, Serratia, Aspergillus, Nocardia, Burkholderia.
## Leukocyte Adhesion Deficiency (LAD)
### LAD Type I
Leukocyte adhesion deficiency type I is an autosomal recessive disorder caused by mutations in the ITGB2 gene, which encodes CD18, the common beta-2 integrin subunit. CD18 heterodimerizes with three distinct alpha chains to form the leukocyte integrins LFA-1 (CD11a/CD18), Mac-1 or complement receptor 3 (CD11b/CD18), and CR4 (CD11c/CD18). These integrins mediate the firm adhesion of leukocytes to activated endothelium via interactions with intercellular adhesion molecules (ICAMs) and are essential for subsequent transmigration of neutrophils from the vasculature into tissues at sites of infection.
In the absence of functional CD18, neutrophils are unable to firmly adhere to the vascular endothelium or transmigrate into tissues, resulting in a distinctive clinical phenotype. The hallmark of LAD-I is delayed separation of the umbilical cord, which normally separates within 7 to 14 days but may remain attached for over 30 days in affected neonates. Patients develop severe bacterial infections that are characteristically devoid of pus formation, since neutrophils cannot reach the tissue sites of infection despite being produced in normal or increased numbers. A persistent and often striking leukocytosis is present, frequently exceeding 25,000 to 100,000 cells per microliter even between infectious episodes, as neutrophils accumulate in the bloodstream unable to exit into tissues. Additional clinical features include severe periodontitis, recurrent skin infections, omphalitis, and poor wound healing.
Diagnosis of LAD-I is made by flow cytometric demonstration of absent or reduced CD18 expression on the surface of neutrophils, with concomitant reduction in CD11a, CD11b, and CD11c. The severity of clinical disease correlates with the degree of CD18 expression: the severe form, characterized by less than 1% CD18 expression, is typically fatal without HSCT, while the moderate form, with 1 to 30% residual expression, follows a milder clinical course.
### LAD Type II
Leukocyte adhesion deficiency type II results from a defect in the GDP-fucose transporter encoded by the SLC35C1 gene. This transporter is required for the fucosylation of selectin ligands, including sialyl-Lewis X (sLex/CD15s), which mediates the initial rolling of leukocytes along the activated endothelium. Without proper fucosylation, selectin-mediated rolling is impaired, leading to defective leukocyte recruitment to sites of infection. Patients with LAD-II exhibit the Bombay blood group phenotype due to absent H antigen, which also requires fucosylation for its synthesis. The infections in LAD-II are generally less severe than those in LAD-I. Additional features include intellectual disability and short stature. Treatment with oral fucose supplementation may partially correct the adhesion defect in some patients.
### LAD Type III
Leukocyte adhesion deficiency type III is caused by mutations in FERMT3, encoding kindlin-3, a protein critical for inside-out integrin activation. Without functional kindlin-3, integrins are expressed on the cell surface but cannot be activated to adopt their high-affinity ligand-binding conformation. The clinical phenotype combines the LAD-I-like infectious susceptibility with a bleeding diathesis resembling Glanzmann thrombasthenia, as platelet integrin (alphaIIbbeta3) function is also impaired. Treatment requires HSCT.
## Other Neutrophil Disorders
### Chediak-Higashi Syndrome
Chediak-Higashi syndrome is an autosomal recessive disorder caused by mutations in the LYST gene, which encodes the lysosomal trafficking regulator. This protein is essential for normal lysosomal biogenesis and granule morphology across all granulated cell types. The hallmark pathologic finding is the presence of giant granules in neutrophils, melanocytes, platelets, and neurons, reflecting abnormal fusion of lysosomes and other granule compartments.
Clinically, Chediak-Higashi syndrome presents with a triad of partial oculocutaneous albinism (due to abnormal melanin granule distribution in melanocytes), recurrent pyogenic infections (due to impaired neutrophil degranulation and chemotaxis), and progressive neurologic dysfunction. The peripheral blood smear reveals pathognomonic giant azurophilic granules within neutrophils, which are virtually diagnostic. The most feared complication is the accelerated phase, a hemophagocytic lymphohistiocytosis-like syndrome that develops in approximately 85% of patients and is often fatal without treatment. The accelerated phase is characterized by pancytopenia, hepatosplenomegaly, lymphohistiocytic tissue infiltration, and hemophagocytosis. HSCT performed before the onset of the accelerated phase offers the best chance for long-term survival, though it does not prevent the progressive neurologic decline.
### Neutrophil-Specific Granule Deficiency
Neutrophil-specific granule deficiency is an autosomal recessive condition caused by mutations in the C/EBPepsilon gene, a transcription factor essential for the formation of specific (secondary) granules during neutrophil maturation. Affected neutrophils lack the contents of specific granules, including lactoferrin and collagenase, which are important for antimicrobial defense and tissue migration. On the peripheral blood smear, neutrophils characteristically display bilobed nuclei resembling the Pelger-Huet anomaly. Patients present with recurrent skin and deep tissue infections and a generally poor inflammatory response. Diagnosis is established by demonstrating the absence of specific granule contents (such as lactoferrin) and the characteristic bilobed nuclear morphology.
### Myeloperoxidase (MPO) Deficiency
Myeloperoxidase deficiency is the most common inherited neutrophil enzyme deficiency, with a prevalence of approximately 1 in 2,000 to 4,000 individuals. MPO catalyzes the conversion of hydrogen peroxide to hypochlorous acid (HOCl) within the phagosome, a potent microbicidal oxidant. Despite the importance of this enzyme in the oxidative killing pathway, the vast majority of MPO-deficient individuals are clinically asymptomatic, likely because redundant microbicidal mechanisms compensate adequately. Rarely, MPO deficiency is associated with disseminated candidiasis, particularly in patients with concurrent diabetes mellitus. The DHR flow cytometry assay is normal in MPO deficiency because the upstream NADPH oxidase remains intact; MPO activity is assessed by specific MPO staining. Most patients with MPO deficiency do not require any specific treatment.
### Severe Congenital Neutropenia (SCN/Kostmann Syndrome)
Severe congenital neutropenia is characterized by a persistently reduced absolute neutrophil count below 500 cells per microliter, resulting from a maturation arrest at the promyelocyte stage of granulopoiesis. Several genetic causes have been identified, including mutations in ELANE (the most common, inherited in autosomal dominant fashion), HAX1 (the gene responsible for the originally described autosomal recessive Kostmann syndrome), G6PC3, and JAGN1. Affected infants present with life-threatening bacterial infections from early in life.
Treatment with granulocyte colony-stimulating factor (G-CSF, filgrastim) raises the absolute neutrophil count in most patients and has transformed the prognosis of this disease. Patients who are refractory to G-CSF should be considered for HSCT. An important long-term concern is the risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), which carries a cumulative incidence of approximately 20% over 20 years. Acquired mutations in the G-CSF receptor gene (CSF3R) may precede malignant transformation and should be monitored.
A clinical comparison chart of major phagocyte defects. Five rows for CGD, LAD-I, LAD-II, Chediak-Higashi, and SCN. Columns: Gene/Protein defect, Inheritance, Pathophysiology (with mini-diagram of affected step: CGD = killing, LAD = adhesion, Chediak-Higashi = granule trafficking, SCN = production), Key Clinical Features (CGD: catalase-positive infections and granulomas; LAD: delayed cord separation, no pus, leukocytosis; Chediak-Higashi: albinism, giant granules, accelerated phase; SCN: ANC<500, promyelocyte arrest), Diagnostic Test (DHR for CGD, CD18 flow for LAD, peripheral smear for Chediak-Higashi, ANC monitoring for SCN), and Treatment (prophylaxis and HSCT for CGD, HSCT for LAD-I severe, G-CSF for SCN). Each row has a characteristic microscopy image: giant granules for Chediak-Higashi, bilobed nuclei for granule deficiency.
| Phagocyte Disorder | Gene/Protein | Defective Step | Key Clinical Features | Diagnostic Test | Treatment |
|---|---|---|---|---|---|
| CGD | CYBB (gp91phox) or NCF1/CYBA/NCF2 | Intracellular killing (oxidative burst) | Catalase-positive infections (Staph, Serratia, Aspergillus, Nocardia); granulomas; CGD colitis | DHR flow cytometry (absent fluorescence) | TMP-SMX + itraconazole + IFN-gamma prophylaxis; HSCT |
| LAD Type I | ITGB2 (CD18) | Firm adhesion and transmigration | Delayed cord separation; infections without pus; leukocytosis (25,000-100,000); periodontitis | Flow cytometry: absent CD18 | HSCT for severe (<1% CD18) |
| LAD Type II | SLC35C1 (GDP-fucose transporter) | Selectin-mediated rolling | Bombay blood group; intellectual disability; less severe infections | Absent sLex (CD15s) | Oral fucose supplementation |
| LAD Type III | FERMT3 (kindlin-3) | Integrin activation | LAD-I-like infections + Glanzmann-like bleeding | Integrin activation assays | HSCT |
| Chediak-Higashi | LYST | Granule trafficking | Partial albinism; giant granules on smear; accelerated phase (HLH) | Peripheral smear: giant azurophilic granules | HSCT before accelerated phase |
| Specific granule deficiency | C/EBPepsilon | Specific granule formation | Recurrent infections; bilobed nuclei (Pelger-Huet-like) | Absent lactoferrin; bilobed nuclei on smear | Supportive |
| MPO deficiency | MPO | HOCl generation | Usually asymptomatic; rarely disseminated candidiasis with DM | MPO staining (DHR is normal) | Usually none required |
| SCN (Kostmann) | ELANE, HAX1, G6PC3 | Neutrophil production | ANC <500; severe bacterial infections from infancy | Bone marrow: promyelocyte arrest | G-CSF; HSCT if refractory; monitor for MDS/AML |
## Hyper-IgE Syndromes
### AD-HIES (Job Syndrome) - STAT3 LOF
Autosomal dominant hyper-IgE syndrome, also known as Job syndrome, is caused by dominant-negative loss-of-function mutations in STAT3, the signal transducer and activator of transcription 3. STAT3 plays a central role in signaling downstream of multiple cytokine receptors, and its loss disrupts Th17 cell differentiation (STAT3 is required for expression of the lineage-defining transcription factor RORgammat), leading to susceptibility to mucocutaneous candidiasis and staphylococcal infections.
The classic clinical triad consists of markedly elevated serum IgE (typically exceeding 2,000 IU/mL), peripheral eosinophilia, and recurrent staphylococcal abscesses. The abscesses in AD-HIES are characteristically described as "cold abscesses" because they lack the expected warmth and erythema of typical pyogenic infections, reflecting impaired local cytokine-mediated inflammation. The syndrome has distinctive multisystem involvement beyond immunodeficiency. Skeletal abnormalities include retained primary teeth (failure of deciduous tooth exfoliation), pathologic fractures secondary to osteopenia, scoliosis, and craniosynostosis. Connective tissue manifestations include a characteristic facies with a broad nasal bridge and prominent forehead, as well as joint hyperextensibility. Pulmonary complications are particularly problematic: recurrent pneumonias lead to pneumatocele formation, and these pneumatoceles may become secondarily colonized with Pseudomonas or Aspergillus species. Vascular anomalies, including coronary artery aneurysms and berry aneurysms, have been increasingly recognized.
Diagnosis is supported by the NIH HIES scoring system, which assigns points for clinical and laboratory features, and confirmed by STAT3 gene sequencing. Treatment includes prophylactic trimethoprim-sulfamethoxazole and antifungal agents, immunoglobulin replacement if specific antibody deficiency is documented, and surgical management of pneumatoceles when necessary.
### AR-HIES (DOCK8 Deficiency)
Autosomal recessive hyper-IgE syndrome is most commonly caused by mutations in DOCK8, a cytoskeletal regulatory protein involved in lymphocyte migration and immune synapse formation. Patients present with elevated IgE, eosinophilia, and a markedly different infectious profile compared to STAT3-deficient HIES. The hallmark is severe and often widespread viral skin infections, including herpes simplex virus, human papillomavirus, and molluscum contagiosum. Food allergies, asthma, and anaphylaxis are notably more common in DOCK8 deficiency than in AD-HIES. There is an increased risk of malignancy, particularly HPV-driven squamous cell carcinoma and lymphoma.
In contrast to STAT3 HIES, DOCK8 deficiency does not produce the skeletal, dental, or connective tissue abnormalities characteristic of Job syndrome. Immunologic evaluation reveals T cell lymphopenia and diminished natural killer cell function. HSCT is curative and dramatically improves the viral susceptibility, making it the treatment of choice for patients with a suitable donor.
## Key Clinical Pearls
- CGD is diagnosed by DHR flow cytometry (not NBT); catalase-positive organisms (Staph, Serratia, Aspergillus, Nocardia) are the hallmark pathogens
- CGD prophylaxis triad: TMP-SMX + itraconazole + IFN-gamma reduces infections significantly
- LAD-I presents with delayed umbilical cord separation, leukocytosis, and infections without pus; diagnose by absent CD18 on flow cytometry
- Chediak-Higashi syndrome has giant granules on peripheral smear and partial albinism; accelerated phase (HLH) is life-threatening
- MPO deficiency is the most common neutrophil defect but is usually clinically silent
- AD-HIES (STAT3) has cold abscesses, pneumatoceles, retained primary teeth, and skeletal abnormalities; AR-HIES (DOCK8) has severe viral skin infections and food allergy
- HSCT is increasingly recommended for severe CGD (especially X-linked gp91phox) with excellent outcomes using modern conditioning regimens
## References
1. Holland SM. Chronic granulomatous disease. *Hematol Oncol Clin North Am*. 2013;27(1):89-99.
2. Gallin JI, et al. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. *N Engl J Med*. 1991;324(8):509-516.
3. Etzioni A, et al. Leukocyte adhesion deficiencies: molecular basis and clinical consequences. *Immunol Rev*. 2002;85:54-66.
4. Freeman AF, Holland SM. The hyper-IgE syndromes. *Immunol Allergy Clin North Am*. 2008;28(2):277-291.
5. Kang EM, et al. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. *J Allergy Clin Immunol*. 2011;127(6):1319-1326.